Navigation Links
ALS Therapy Development Institute and Oxford BioMedica Begin Second Phase of Collaboration to Develop Gene Therapies for Amyotrophic Lateral Sclerosis
Date:1/27/2010

l growth factor.  Furthermore, the joint team plans to evaluate other potentially therapeutic genes that inhibit or regulate specific genetic pathways associated with disease onset or progression.

Oxford BioMedica's Chief Executive Officer, John Dawson, commented: "The successful completion of the first phase of the collaboration is testament to the quality of the scientific teams at the ALS TDI and Oxford BioMedica. Our LentiVector technology has unique capabilities to deliver genes safely and efficiently to neuronal cells and our product candidate, MoNuDin, has shown promising results in preclinical models of ALS. The extension of our collaboration with the ALS TDI enables us to accelerate MoNuDin's development and to explore new disease pathways as potential targets for genetic intervention. We are delighted to have ongoing support from the Muscular Dystrophy Association for our collaboration with the ALS TDI, which underscores our shared goal to develop new treatment options for patients suffering from ALS."

The Muscular Dystrophy Association's Augie's Quest Initiative is a major donor to the ALS TDI and provided the critical funding needed to execute the collaboration between Oxford BioMedica and the ALS TDI.

About ALS TDI

The mission of the ALS Therapy Development Institute (ALS TDI) is to develop effective therapeutics that slow or stop amyotrophic lateral sclerosis (ALS, Lou Gehrig's disease), as soon as possible.  Focused on meeting this urgent unmet medical need, ALS TDI executes a robust discovery program, while running the world's largest efforts to pre-clinically validate potential therapeutics; including small molecules, protein biologics, gene therapies and cell-based constructs.  The world's first non-profit biotech, ALS TDI has developed an industrial-scale platform that allows for the development and testing of do
'/>"/>

SOURCE ALS Therapy Development Foundation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
2. Medinet Licenses MaxCyte Cell Loading Technology for Cancer Immunotherapy in Japan
3. Exelixis Reports Encouraging Interim Data From a Phase 2 Trial of XL647 as First-Line Therapy for Non-Small Cell Lung Cancer
4. Study Supports Use of GlycoMark Blood Test to Evaluate Therapy in Children with Diabetes
5. Elekta To Showcase Innovations in Radiotherapy and Unveil New Product That Expands Cancer Treatment Availability
6. Elekta Contract Provides Sisters of Mercy Health System Access to Leading Radiation Therapy Solutions
7. Varian Medical Systems Exhibits Latest Technologies and Products Designed to Improve Speed and Precision of Radiotherapy at ESTRO 2007
8. Elekta Displays Complete Volumetric Intensity Modulated Arc Therapy Solutions at ESTRO
9. Stem Cell Therapy to Skyrocket by 2017
10. Team demos safety of RNA therapy
11. First European IGRT School Takes Place for Radiotherapy Practitioners in UK
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2015)... 31, 2015 Research and Markets ( http://www.researchandmarkets.com/research/v7fdpx/argentina ... Biomedical Sensors Market - Growth, Trends & Forecasts (2014-2020)" ... Argentina Biomedical Sensors market is estimated at $0.17 billion ... period 2014-2020 The near future will bring ... of each individual. These sensors can be set to ...
(Date:8/31/2015)... 31, 2015 /PRNewswire/ - Portage Biotech Inc. ("Portage" or ... is pleased to announce that its wholly owned subsidiary, ... candidate, PPL-003, to an Investigational New Drug (IND) application ... uveitis.  PPL recently completed a study in a rat ... achieved highly significant efficacy and a more rapid onset ...
(Date:8/31/2015)... , Aug. 31, 2015 LabStyle Innovations ... Management Solution, today announced it recently closed a ... will be used to support the global rollout ... a mobile, cloud-based, diabetes management solution that includes ... pocket-sized, blood glucose monitoring device, and for working ...
(Date:8/31/2015)... ... 2015 , ... Proove Biosciences, Inc. is a finalist for the Outstanding Tech ... , Now in its 22nd year, this premier awards event celebrates the best in ... and around the world. The OC Tech Alliance will announce all winners at a ...
Breaking Biology Technology:Argentina Biomedical Sensors Market Report 2015 - Growth, Trends & Forecasts 2014-2020 2Portage's PPL will advance its lead candidate PPL-003 to an IND for dry eye disease and uveitis 2Portage's PPL will advance its lead candidate PPL-003 to an IND for dry eye disease and uveitis 3LabStyle Innovations Closes $2.5 Million Funding to Support Global Rollout of Dario Diabetes Management Solution 2LabStyle Innovations Closes $2.5 Million Funding to Support Global Rollout of Dario Diabetes Management Solution 3LabStyle Innovations Closes $2.5 Million Funding to Support Global Rollout of Dario Diabetes Management Solution 4Proove Biosciences, Inc. Named a Finalist for 22nd OC Tech Alliance High-Tech Awards for Company of the Year 2Proove Biosciences, Inc. Named a Finalist for 22nd OC Tech Alliance High-Tech Awards for Company of the Year 3Proove Biosciences, Inc. Named a Finalist for 22nd OC Tech Alliance High-Tech Awards for Company of the Year 4
... Inc. announced today that it has been awarded funding ... pre-clinical research targeting alpha-synuclein, a protein whose clumping is ... NeuroPhage,s first grant from MJFF. "It ... development of our novel therapeutic approach.  This grant will ...
... ARBOR, Mich., Feb. 16, 2012  Adeona Pharmaceuticals, Inc. (NYSE ... DNA-based therapeutics and innovative disease-modifying medicines for serious illnesses, ... of stockholders to change its corporate name to Synthetic ... will start trading under its new name and stock ...
... February 15, 2012 CitiusTech, a leading ... the calendar year 2011 with 59% growth in revenues. ... has recorded over 50% Y-o-Y revenue growth. In 2011, ... healthcare technology. CitiusTech was selected as a finalist at ...
Cached Biology Technology:NeuroPhage Receives Michael J. Fox Foundation Funding for Parkinson's Disease Research 2CitiusTech Completes Another Milestone Year: Revenues Grow by 59% in 2011 2
(Date:8/25/2015)... SALT LAKE CITY and BELLEVUE, ... a global leader in advanced robotic systems, announced today ... first-of-its-kind robotic unmanned ground vehicle (UGV), at the National ... Lake City.  The Guardian S is ... is the culmination of years of research and in-field ...
(Date:8/20/2015)... 2015   Sensory, Inc ., a Silicon ... experience and security of consumer electronics through state-of-the-art ... its TrulySecure™ is the first multimodal ... FIDO Certified™. The FIDO (Fast Identification ... FIDO UAF (Universal Authentication Framework) 1.0 specifications, which ...
(Date:8/18/2015)... 17, 2015 Research and Markets ( ... "Global Biometric Authentication & Identification Market: Focus ... Forecast, 2015-2020" report to their offering. ... systems market is expected to grow at an ... and generate over $25 billion (approximately) by 2020 ...
Breaking Biology News(10 mins):Sarcos to Debut First-of-its-Kind Snake Robot 2Sarcos to Debut First-of-its-Kind Snake Robot 3TrulySecure From Sensory Becomes First Face and Voice Biometrics Technology to be FIDO UAF Certified 2TrulySecure From Sensory Becomes First Face and Voice Biometrics Technology to be FIDO UAF Certified 3TrulySecure From Sensory Becomes First Face and Voice Biometrics Technology to be FIDO UAF Certified 4TrulySecure From Sensory Becomes First Face and Voice Biometrics Technology to be FIDO UAF Certified 5Global Biometric Authentication & Identification Market 2015: Focus On Modality, Motility & Application - Estimation & Forecasts to 2020 for the $25 Billion Industry 2
... Scientists have identified a genetic variation in people ... muscle cells respond to the hormone insulin, in a ... The researchers, from Imperial College London and other international ... scientists developing treatments for diabetes. Previous studies have ...
... to restore to normal levels a key protein involved ... have been shown to cause the rare brain disorder ... mental retardation and very early death in human infants. ... mice, that the genetic equivalent to human lissencephaly, also ...
... what you know often comes at the price of learning ... easy for many, but not for those with conditions such ... simple routines. Using brain scans in monkeys, Duke ... monkeys will switch from exploiting a known resource to exploring ...
Cached Biology News:Scientists discover new genetic variation that contributes to diabetes 2Researchers restore missing protein in rare genetic brain disorder 2Researchers restore missing protein in rare genetic brain disorder 3Monkey brains signal the desire to explore 2
... Timp-4 has been reported in heart ... fibroblasts in cell culture conditions. ... TPA stimulates production of TIMP-4 in ... protein levels produced often require concentration ...
Goat polyclonal to HSPC150 ( Abpromise for all tested applications). entrezGeneID: 29089...
Anti-MMP-13 Collagenase-3, amino terminal end of active enzyme; rabbit host...
...
Biology Products: